Skip to main
GOSS

GOSS Stock Forecast & Price Target

GOSS Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 29%
Buy 43%
Hold 14%
Sell 14%
Strong Sell 0%

Bulls say

Gossamer Bio is a clinical-stage biopharmaceutical company that is focusing on developing innovative treatments for diseases in immunology, inflammation, and oncology areas. The company has a promising pipeline product, Seralutinib, which is addressing a high unmet need in the pulmonary arterial hypertension (PAH) market. The recent updates from the company, including a positive Type B meeting with the FDA and favorable CT FRI data, reaffirm the company's strong regulatory and clinical narrative. Additionally, the recent completion of its convertible note exchange offer reflects creditors' confidence in the company's ability to successfully execute its regulatory plans. While there are still risks and uncertainties, the current valuation does not fully factor in the potential approval and launch of Seralutinib, and therefore, this analyst maintains a positive outlook on Gossamer Bio's stock.

Bears say

Gossamer Bio is expected to face challenges in the development, commercialization, and reimbursement of their primary product candidate, seralutinib, as well as potential dilution risks and pricing uncertainties. Additionally, the reversible and monitorable safety profile of seralutinib is not enough to offset concerns over its failure to meet primary endpoint in PAH trials and potentially limited efficacy in PH-ILD. Overall, the company's market cap of $1.1 billion seems overvalued.

GOSS has been analyzed by 7 analysts, with a consensus rating of Buy. 29% of analysts recommend a Strong Buy, 43% recommend Buy, 14% suggest Holding, 14% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Gossamer Bio Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Gossamer Bio Inc (GOSS) Forecast

Analysts have given GOSS a Buy based on their latest research and market trends.

According to 7 analysts, GOSS has a Buy consensus rating as of Aug 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $2.90, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $2.90, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Gossamer Bio Inc (GOSS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.